Adenosinergic Signaling as a Key Modulator of the Glioma Microenvironment and Reactive Astrocytes

Gabriela N. Debom†, Dominique S. Rubenich† and Elizandra Braganhol†,2*

1 Programa de Pós-graduação em Biociências, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil, 2 Instituto de Cardiologia do Rio Grande do Sul, Instituto de Cardiologia - Fundação Universitária de Cardiologia, Porto Alegre, Brazil

Astrocytes are numerous glial cells of the central nervous system (CNS) and play important roles in brain homeostasis. These cells can directly communicate with neurons by releasing gliotransmitters, such as adenosine triphosphate (ATP) and glutamate, into the multipartite synapse. Moreover, astrocytes respond to tissue injury in the CNS environment. Recently, astrocytic heterogeneity and plasticity have been discussed by several authors, with studies proposing a spectrum of astrocytic activation characterized by A1/neurotoxic and A2/neuroprotective polarization extremes. The fundamental roles of astrocytes in communicating with other cells and sustaining homeostasis are regulated by purinergic signaling. In the CNS environment, the gliotransmitter ATP acts cooperatively with other glial signaling molecules, such as cytokines, which may impact CNS functions by facilitating/inhibiting neurotransmitter release. Adenosine (ADO), the main product of extracellular ATP metabolism, is an important homeostatic modulator and acts as a neuromodulator in synaptic transmission via P1 receptor sensitization. Furthermore, purinergic signaling is a key factor in the tumor microenvironment (TME), as damaged cells release ATP, leading to ADO accumulation in the TME through the ectonucleotidase cascade. Indeed, the enzyme CD73, which converts AMP to ADO, is overexpressed in glioblastoma cells; this upregulation is associated with tumor aggressiveness. Because of the crucial activity of CD73 in these cells, extracellular ADO accumulation in the TME contributes to sustaining glioblastoma immune escape while promoting A2-like activation. The present review describes the importance of ADO in modulating astrocyte polarization and simultaneously promoting tumor growth. We also discuss whether targeting of CD73 to block ADO production can be used as an alternative cancer therapy.

Keywords: tumor microenvironment, glioblastoma, tumor-associated astrocyte, A2-like astrocyte, adenosine, CD73
INTRODUCTION

In the last few years, astrocytes have received increased attention, with many studies aimed at in-depth understanding of their functions in the healthy brain and in central nervous system (CNS) pathologies (Khakh and Sofroniew, 2015; Escartin et al., 2019). Reactive astrocyte responses have been described as detrimental in different pathologies, including neuroinflammatory and neurodegenerative diseases and brain tumors (Liddelow and Barres, 2017).

In this regard, glioblastoma (GB) is the most common and aggressive primary tumor in the CNS (Huse and Holland, 2010). Although many researchers have attempted to develop new therapeutic strategies for GB, patients continue to show a short median survival time (Huse and Holland, 2010; Noroese et al., 2016; Di Carlo et al., 2019). The tumor microenvironment (TME) contains not only GB cells, but other normal cells such as immune cells and astrocytes that contribute to cancer progression and may shape the tumor cell response to radio-chemotherapy (Wang et al., 2017; Najafi et al., 2019; Wei et al., 2020). Therefore, GB-astrocyte crosstalk may explain the poor prognosis of patients by improving the understanding of how astrocytes contribute to GB progression, which can provide new biological treatment targets (Brandao et al., 2019).

The presence of extracellular adenosine triphosphate (ATP) and its hydrolysis products, namely ADP, AMP, and adenosine (ADO), triggers the purinergic signaling cascade (Burnstock, 2007; Di Virgilio et al., 2009). The biological effects of extracellular purines and pyrimidines are mediated by P1 and P2 purinoceptors (Zarrinmayeh and Territo, 2020). ADO mediates the sensitization of the P1 receptors named A1R, A2AR, A2BR, and A3R (Fredholm et al., 2011). The P2 family is subdivided into ionotropic P2X (1–7) and metabotropic P2Y (P2Y1, 2, 4–6, 11, 12, 13, 14) receptors (Burnstock, 2007; Di Virgilio et al., 2018). ATP plays a dual role in the TME by exhibiting anti- or pro-tumor effects depending on its extracellular concentration, the presence of purinergic receptors, and the combined activity of ectonucleotidases, such as ecto-nucleoside-triphosphate-diphosphohydrolases (E-NTPDases) and CD73, which metabolize ATP to ADO in the extracellular space (Allard et al., 2016, 2017). The amplitude of the agonist effects of ATP and its metabolite ADO is critical for maintaining the TME, as these signaling molecules have tumor-promoting activities in immune escape, angiogenesis, cell proliferation, and migration (Allard et al., 2016, 2020; Di Virgilio et al., 2016, 2018). In addition, extracellular ATP and ADO have important roles in neurodegenerative, cognitive, and psychiatric disorders. ADO modulates synapse function by altering neuron firing in different brain regions, contracting the local vasculature, and exerting immune/neuromodulatory effects (Dunwiddie, 1985; Redzic et al., 2010; Hinton et al., 2014; Allard et al., 2016; Di Virgilio et al., 2016). In this regard, selective participation of purinergic signaling in astrocytes has been well-established and recently reviewed (Illes et al., 2019; Agostinho et al., 2020; Lopes et al., 2021). However, astrocitic polarization has recently gained attention, although little is known about the contribution of extracellular purines to A1/neurotoxic or A2/neuroprotective astrocyte polarization. The present review summarizes the available evidence on the participation of purinergic signaling, mostly involving ADO, in modulating the astrocyte phenotype in the TME and its further impact on GB progression.

ROLE OF REACTIVE ASTROCYTES IN THE BRAIN

Astrocytes are abundant and complex glial cells in the CNS and are key elements involved in brain homeostasis (Sofroniew and Vinters, 2010). Astrocytes establish and maintain the blood–brain barrier with their cell end-feet (Ballabh et al., 2004; Verkhratsky and Nedergaard, 2018). Moreover, these glial cells are tightly integrated into neural networks, participating in synaptic transmission regulation via uptake of the neurotransmitter glutamate, and communicate with neighboring cells through Ca2+ signals (Clarke and Barres, 2013). Astrocytes form a fundamental part of synaptology together with the pre- and postsynaptic neuronal compartments as part of the multiparticle synapse (Verkhratsky and Nedergaard, 2018).

Astrocytes undergo a set of morphological changes in their normal state in response to CNS insults (Wilhelmsson et al., 2006; Sofroniew, 2009; Burda et al., 2016; Liddelow et al., 2017). The reactivity of astrocytes is a universal reaction that occurs in response to cerebral injury. Under stress condition, these cells assume a wide range of new characteristics in brain, becoming hypertrophic, upregulating intermediate filaments such as nestin, vimentin, and glial fibrillary acidic protein, and in some cases, activating proliferation process (Pekny and Pekna, 2014; Boccazzi and Ceruti, 2016; Guan et al., 2018). Reactive astrocytes are observed in the brains of patients suffering from various pathological conditions, including trauma, infection, neurodegeneration, and ischemia (Zamanian et al., 2012).

Because of their variable roles in different pathological conditions, reactive astrocytes remain controversial. Although they are recognized as the pathological hallmark of CNS structural lesions, previous studies reported that, in addition to supporting CNS recovery, astrocytes could inhibit axon regeneration after CNS injury and produce proinflammatory cytokines that exacerbate neuroinflammatory damage (Sofroniew and Vinters, 2010; Zamanian et al., 2012; Liddelow et al., 2017). Recently, astrocytes were shown to react to insults in an activation spectrum, similar to that observed in macrophages and microglia in the CNS, assuming two opposite phenotypes in a spectrum of polarization: A1-astrocyte and A2-astrocyte (Liddelow and Barres, 2017; Figure 1A). A1-astrocytes are neurotoxic and associated with injuries and neurodegenerative pathologies such as Alzheimer’s disease (Goetzl et al., 2018; Carter et al., 2019; Grimaldi et al., 2019), Parkinson’s disease (Hinkle et al., 2019), and Huntington’s disease (Diaz-Castro et al., 2019). Moreover, A1-astrocyte polarization has been associated with normal brain aging, which supports the involvement of A1-astrocytes in neuroinflammation (Clarke et al., 2018). In contrast, A2-astrocytes tend to be neuroprotective and promote neuronal survival (Singh et al., 2019). Therefore, once induced, these two extremes of cell phenotypes diverge in gene expression, cell...
structure, signaling, and overall function (Escartin et al., 2019). The plasticity of astrocytes that enables them to exert diverse responses to injuries has become a topic of research interest, representing an opportunity to explore specific therapeutic strategies for brain pathologies including GB (Pavlou et al., 2019).

**TUMOR MICROENVIRONMENT OF THE BRAIN: THE IMPORTANCE OF MICROGLIA-ASTROCYTE CROSSTALK**

Glioblastoma is considered as the most common and aggressive primary brain tumor, accounting for more than 40% of neoplasms of the CNS (Huse and Holland, 2010; Di Carlo et al., 2019). Clinically, gliomas are divided into four degrees, grade I as benign, which show slow proliferation rate and good prognosis after surgical removal; grade II gliomas, which are slightly more severe and capable of progressing to higher grades; and grade III and IV gliomas, which are the most aggressive and characterized by a high rate of cell proliferation, spreading rapidly through the normal parenchyma of the CNS (Nørøxe et al., 2016; Verano-Braga et al., 2018). Moreover, GB (grade IV glioma) exhibits higher angiogenesis and necrosis when compared to grade I–III gliomas, resulting in a short survival time of approximately 15 months in patients (Huse and Holland, 2010; Di Carlo et al., 2019). The first-choice treatment for GB involves surgical removal combined with radio-chemotherapy with temozolomide (TMZ), a DNA-alkylating agent (Stupp et al., 2005).

The TME directly influences tumor growth and proliferation. The GB microenvironment comprises infiltrating and resident immune cells, vascular cells, and glial cells such as astrocytes and microglia (Chen and Hambardzumyan, 2018; Figure 1B). The interactions of tumor cells with non-malignant cells in the TME occur via direct cell-cell communication, shape tissue reorganization, and tumor ecosystem modulation (Tirosh and Suvà, 2018), and impact the biology and aggressiveness of GB (Azambuja et al., 2020a).

Tumor-associated macrophages are the dominant infiltrating immune cell population in the tumor mass, constituting \( \sim 30–40\% \) of total cells of the GB bulk (Hambardzumyan et al., 2016; Chen and Hambardzumyan, 2018). Microglia, as the resident innate immune cell of the CNS, is also abundant in the GB TME (Charles et al., 2011). Both macrophages and microglia display an alternative phenotype of activation or M2-like polarization when subverted by the tumor signals associated with growth, invasion, and angiogenesis, in addition to contributing to the establishment of an immunosuppressive environment (Da Fonseca et al., 2016; Placone et al., 2016; Matias et al., 2017; Roesch et al., 2018). In addition to macrophages and microglia, lymphocytes are recruited to the tumor site, a relevant part of the TME. A higher proportion of CD4\(^+\) than CD8\(^+\) cells in the TME is associated with a high tumor grade and worst prognosis (Gieriying et al., 2017; Strepkos et al., 2020).

Other non-neoplastic cells are found in smaller numbers, such as oligodendrocyte precursor cells and neurons. Although there is limited evidence explaining the contribution of glial cells to immunosuppression, these cells have the potential to alter the TME (Henrik Heiland et al., 2019). Communication among these different cell types is an important process carried out by the exchange of information via extracellular vesicles, including exosomes, containing signaling proteins or regulatory RNAs (Rajendran et al., 2014).

The interaction of GB cells with astrocytes around the peritumoral area has become a topic of great interest. Reactive astrocytes exhibit intimate crosstalk with activated microglia and similar secreted factors such as interleukin-1\(\beta\), interleukin-6, and nitric oxide, which are related to GB progression.
However, in the extracellular environment, this nucleotide is crucial for the maintenance of physiological functions including neuro/gliotransmission and immune/inflammatory responses (Khakh and Burnstock, 2009). ATP can be metabolized to ADO by ectonucleotidases, such as CD39 (NTPDase1) and CD73 (ecto-5'-nucleotidase), which play key roles by producing active hydrolyzed products and recycling nucleotides (Burnstock, 2007; Allard et al., 2017). Adenosine deaminase (ADA) is responsible for converting ADO to inosine, and both ADO and inosine can be transported across cellular membranes through nucleoside transporters (ENTs) (Boswell-Casteel and Hays, 2017; Pastor-Anglada and Pérez-Torras, 2018; Figure 2A).

ATP is considered as a danger-associated molecule that is released by injured cells into the extracellular medium during inflammation (Minkiewicz et al., 2013). In addition, ATP can be released by astrocytes through specific and regulated pathways such as exocytosis (Pangršiˇc et al., 2007), vesicular release (Coco et al., 2003; Zorec et al., 2016), or diffusion through ion channels, specifically pannexin/connexin channels (Stout et al., 2002; Suadicani et al., 2012). Increasing evidence has demonstrated that both astrocytes and tumor cells express purinergic receptors and purine-metabolizing enzymes, which can trigger a set of biological effects in the CNS (Wink et al., 2003, 2006; Rodrigues et al., 2015; Azambuja et al., 2019a; Illes et al., 2019; Campos-Contreras et al., 2020). In line with this, ATP and ADO signaling may have significant impacts on therapies for brain tumors such as GB (Azambuja et al., 2019a, b, 2020c).

Astrocytes release various gliotransmitters, such as glutamate, D-serine, and ATP (Figure 2B). Notably, after activation, a single astrocyte releases both glutamate and ATP in the multiparticle synapse, leading to biphasic modulation of synaptic transmission (Ma et al., 2016). Extracellular ATP is well-known for its role in mediating astrocytic Ca2+ waves (Guthrie et al., 1999) as well as in astrocyte-mediated wound healing in glial scars (Singh et al., 2015). Moreover, the catalysis of ATP likely represents the source of ADO inactivating postsynaptic A2AR (Agostinho et al., 2020), as well as the mechanism by which the release of gliotransmitters by astrocyte exerts neuronal feedback actions and eventually modulates synaptic transmission and plasticity (Illes et al., 2019; Schems et al., 2019).

As described above, microglia-astrocyte crosstalk is instrumental to CNS functions and determines the fate of astrocytes and microglia activation (Jha et al., 2019). Microglial activation by lipopolysaccharide, a TLR4 agonist, induces the release of ATP, which in turn stimulates P2Y1 in astrocytes, leading to the release of glutamate and further modulation of neuronal activity (Pascual et al., 2012). Cortical astrocytes respond to extracellular ATP under in vitro experimental conditions, and astrocytic activation into a reactive phenotype, including cell proliferation and glial fibrillary acidic protein remodeling, depends on ATP levels (Suadicani et al., 2012). Similarly, Ficker et al. (2014) found a correlation between P2X7 receptor sensitization and the development of inflammatory and neuropathic pain, possibly involving oxidative stress.

ATP can be converted into its breakdown product ADO in the extracellular environment by ectonucleotidases. A previous study reported a purinergic enzyme profile for E-NTPDases (Liddleow and Barres, 2017; Jha et al., 2019) and a poor prognosis for patients (Mega et al., 2020). This relationship may also be essential for the immune aspects of the brain tumor TME. Placone et al. (2016) suggested that astrocytes promote the proliferation and invasion of tumor cells and decrease chemotherapeutic efficiency by protecting malignant cells from apoptosis (Chen et al., 2015). Moreover, astrocytes cleave the inactive form of matrix metalloproteinase-2 (pro-MMP2) to matrix metalloproteinase 2, which is involved in tumor invasiveness (Le et al., 2003). Brandao et al. (2019) demonstrated that astrocytes are involved in GB progression, identifying reactive astrocytes around the tumor as tumor-associated astrocytes characterized by high proliferation, migration, and invasion to support tumor cell survival. Studies have demonstrated that astrocytes release exosome vesicles (EVs) containing promoters of angiogenesis and immune modulation, further supporting the novel capabilities of astrocytes in communicating with the TME (Proia et al., 2008; Hajrasouliha et al., 2013). Additionally, Leiss et al. (2020) highlighted astrocyte-glioma crosstalk, indicating that platelet-derived growth factor is a potential astrocytic biomarker associated with a poor prognosis in patients with GB.

Astrocytes in the peritumoral areas can be affected by GB, causing leakage through the blood–brain barrier and contributing to the entrance of a set of immune cells at the tumor site (Watkins et al., 2014; Noroxe et al., 2016). The recruitment of new tumor-associated macrophages and regulatory T-cells to the TME and overall immunosuppressive microenvironment are crucial for GB development and progression and are factors that affect the poor response of this tumor to conventional immunotherapy (Joyce and Fearon, 2015; Broekman et al., 2018; Pasqualini et al., 2020).

In summary, tumors control their microenvironment to establish an immunosuppressed niche. The tumor capacity to “educate” non-transformed cells in the TME contributes to escape from surveillance by avoiding an effective immune response against tumor and preventing the recruitment of other adaptive and innate immune cells that may inhibit tumor growth (Da Fonseca et al., 2016). Therefore, tumor cells can effectively alter the immune system from a protective to a detrimental state and favor tumor progression (Chen and Hambardzumyan, 2018). In accordance with these observations, increasing evidence has revealed that astrocytes contribute to the immunosuppressive characteristics of the TME, and that microglia-astrocyte crosstalk is an important subject that requires further study (Placone et al., 2016). Besides that, the discussion about astrocytic activation states into the GB microenvironment needs to be amplified in order to comprehend the complexity of GB phenotypes and the diversity of the tumor ontogeny (Noroxe et al., 2016).

**PURINERGIC SIGNALING IN ASTROCYTES: FROM ADENOSINE TRIPHOSPHATE TO ADENOSINE**

ATP is known for its classic function in energy metabolism. However, in the extracellular environment, this nucleotide is
FIGURE 2 | Purinergic signaling and astrocytes. (A) Intracellular ATP is released from astrocytes via specific channels such as Panx-1. Extracellular ATP and its breakdown products, ADP and ADO, are agonists of purinergic receptors, and the extracellular levels of nucleotides and nucleosides are regulated by (Continued)
and CD73 in rat astrocytes, demonstrating that extracellular ATP is rapidly converted to ADP, and ultimately, to AMP by NTPDase2, an ectoenzyme predominantly expressed in these cells (Wink et al., 2003, 2006). As high levels of extracellular ATP are neurotoxic, NTPDase2 activity in astrocytes may protect neurons from damage, in addition to promoting ADO production (Wink et al., 2006). In addition, CD73 overexpression was observed in reactive astrocytes as a possible protective astrocyte repertoire during the symptomatic phase of an experimental autoimmune encephalomyelitis model, demonstrating the relationship between the ATP/ADO ratio and acute inflammatory situations (Lavrnia et al., 2015). CD73 activity is also involved in astrocyte adhesion and migration, possibly via interactions with the extracellular matrix (Adzic et al., 2017; Adzic and Nedeljkovic, 2018).

In general, ADO is directly related to cellular processes such as viability and adaptability (Cunha, 2016). However, under pathological conditions, the ADO concentration acts as a risk factor for CNS pathologies, including the development/progression of neurodegenerative diseases and brain tumors (Cunha, 2016; Azambuja et al., 2020e). Thus, studies have focused on investigating astrocytic ADO plasticity to understand the role of ADO in pathological situations.

The ability of astrocytes to detect patterns of neural activity is attributed to the fine adjustment of astrocyte signaling, which in turn modulates synaptic transmission and contributes to the most diverse forms of synaptic plasticity (Covelo and Araque, 2018; Mederos et al., 2019). Brain injuries caused by trauma or stroke increase extracellular ADO levels (Haskó et al., 2005; Fusco et al., 2018). In this regard, the P1 receptors A1R and A2AR are located at synapses, particularly at excitatory ones, and cross-communication between astrocytes and neurons regulates the neural networks (Rebola et al., 2008; Illes et al., 2019). Indeed, astrocytes depress excitatory synapses and potentiate inhibitory synapses by activating A1R and A2AR, respectively (Martin-Fernandez et al., 2017). Interestingly, astrocytic A2AR modulates glutamate-mediated signaling through a variety of mechanisms (Rebola et al., 2008). For example, A2AR influences glutamate and GABA uptake by neurons, and selective A2AR activation in astrocytes inhibits glutamate uptake by decreasing Na+/K+-ATPases (NKAs) and the α2 subunit of NKA (Matos et al., 2013). Based on these results, A2AR overexpression observed in astrocyte reactivity contributes to the progression of brain diseases, making this receptor a potential therapeutical target for Alzheimer's disease, Parkinson's disease, and Sandhoff disease, as previously reported and extensively revised (Ohta et al., 2006; Matos et al., 2015; Scharbarg et al., 2016; Basanta and Anderson, 2017; Liddelow and Barres, 2017; Quail and Joyce, 2017; Wesseling and Capper, 2018; Allen et al., 2019; Okada et al., 2019; Schalla and Stengel, 2019; Azambuja et al., 2020d; data summarized in Table 1).

Although A2AR has shown a protagonist effect in studies of neurodegenerative disease, some neuroprotective actions have been reported for A3B R sensitization. Moidunny et al. (2012) observed a positive correlation among astrocytic leukemia inhibitory factor protein expression, A2BR sensitization, and further Gq/11-PLC-PKC-NFκB cascade activation, supporting the neuroprotective effect of A3B R under excitotoxic conditions. In contrast, in an ischemia model, the use of A2BR antagonists (MRS1754 and PSB603) partially limited astrocyte proliferation, thus preventing neurodegenerative effects on neurons (Fusco et al., 2018).

In addition to the relation with astrocytes, purinergic signaling is also an important player in the microglial reactivity. In the CNS, the P2X7 receptor is preferentially located on microglia (Illes, 2020). Besides that, several authors have also been reported the expression of P1 receptors in microglia, describing ADO as a crucial modulator of microglia phenotype of CNS pathologies, including cancer (Hammarberg et al., 2003; Synowitz et al., 2006; Ferreira-Silva et al., 2020).

Extracellular ADO is ultimately converted to inosine by ADA, which exerts many biological regulatory functions such as protecting the brain against neuronal diseases. A very informative study applied an experimental strategy for profiling fibroblasts and inducing neuronal progenitor-derived human-induced astrocytes from patients with amyotrophic lateral sclerosis, to evaluate dysfunctional astrocytic energy metabolism. The investigation revealed that induced human astrocytes had reduced ADA activity, making the astrocytes more susceptible to ADO-induced toxicity. In contrast, restoration of ADA activity and/or supplementation with inosine stimulated the aerobic state of astrocytes, increased the bioenergetic capacity, and decreased neurotoxicity, thereby demonstrating a beneficial therapeutic approach (Allen et al., 2019).

Considering the collective results of previous studies, A1R, A2B R, and ADA activity in astrocytes is crucial for neuronal maintenance and may contribute to the A2/neuroprotective profile of astrocytes. In contrast, overexpression of A2AR disrupts adenosinergic homeostasis and is involved in neuronal degeneration, representing a classic condition of A1/neurotoxic activation in astrocytes. These data are summarized in Table 1. An imbalance of the adenosinergic pathway is common.
| Nucleotide or nucleoside/receptor/channel/enzyme | Biological process | Experimental system | Effect | References |
|-----------------------------------------------|-------------------|---------------------|--------|------------|
| ATP                                           | Neuroinflammation | In vitro            | Induction of astrocytic reactivity by ATP | Adzic et al., 2017 |
| ATP                                           | Neuron and glia plasticity | In vitro            | ATP released as an activation process of astrocytes | Singh et al., 2015 |
| ATP/ADO                                       | Neuron and glia plasticity | In vivo            | ATP/ADO are released downstream of the GABA-mediated astrocyte Ca^{2+} signal | Covelo and Araque, 2018 |
| Panx1                                         | Neuron and glia plasticity | In vivo            | Related to ATP release in astrocytes and better outcome of seizures | Scemes et al., 2019 |
| P2X7                                          | Neuroinflammation and pain | In vivo            | P2X7 receptors as a key mechanism in inducing pain during inflammation | Ficker et al., 2014 |
| CD73                                          | Cell adhesion/migration | In vitro            | Upregulation of CD73 | Adzic and Nedeljkovic, 2018 |
| CD73                                          | Neuroinflammation | In vivo            | Neuroprotection of CD73 overexpression during acute inflammation | Lavrnja et al., 2015 |
| ADO                                           | Neuron and glia plasticity | Cerebral cortex human astrocytes | Inhibition of astrocyte proliferation independent of P1 receptor sensitization | Marcelino et al., 2020 |
| P2Y1 + A2A-R                                  | Neuron and glia plasticity | In vivo            | ATP/ADO release impact synaptic plasticity and enhance cognitive functions | Mederos et al., 2019 |
| rENT-1                                        | Neurodegeneration | In vitro            | Neuroprotection role of ADO after hypoxia and glucose deprivation | Redzic et al., 2010 |
| ENT1                                          | Neurodegeneration | In vitro + In vivo | Reduced GFAP expression in astrocyte cultures ENT1-knockdown, and in ENT1−/− mice | Hinton et al., 2014 |
| AR                                            | Neuron and glia plasticity | In vivo            | Neurromodulation by ATP release from astrocytes and subsequent activation of AR on dopaminergic neurons | Ma et al., 2016 |
| A1R                                           | Neuron and glia plasticity | In vitro + In vivo | Activation of A1-R receptors is increased by wakefulness | Schmitt et al., 2012 |
| A2B-R                                         | Neuron and glia plasticity | In vivo            | Astrocytic ATP and ATP-derived adenosine involved in the cognitive deficits following sleep deprivation | Rorian et al., 2011 |
| A3R                                           | Neuron and glia plasticity | In vivo            | Induction of inflammation via LPS and control of sleep | Nadjar et al., 2013 |
| A3R + A2B-R                                   | Neuron and glia plasticity | In vivo            | Neuroprotective effects | Kong et al., 2020 |
| A1R – A2A-R                                   | Neuron and glia plasticity | In vivo            | Neurromodulation by regulating specific synapses via ATP/ADO | Martin-Fernandez et al., 2017 |
| A2A-R                                         | Neuron and glia plasticity | In vitro            | Role of A2A-R in neuronal protection | Moldunny et al., 2012 |
| A2A-R                                         | Neuron and glia plasticity | In vitro            | Increase in extracellular glucose concentration induces astrocytic ADO release, regulating the need for sleep | Scharbarg et al., 2016 |
| A1R-A2A-R                                     | Neuroinflammation | Surgical specimens from glioma patients | Neuroprotective and anti-convulsive effect | Huang et al., 2016 |
| A2A-R                                         | Neurodegeneration | In vivo            | Neuroprotection after A2A-R antagonism using MSX-3 | Cerri et al., 2014 |
| A3R                                           | Neuron and glia plasticity | In vivo            | Interaction between A3R and D2-dopamine receptors | Cervetto et al., 2018 |
| A3R                                           | Neuron and glia plasticity | In vivo            | Dysfunction of astrocytic A3R triggers the crosstalk between astrocyte and neuron | Matos et al., 2015 |
| A2A-R                                         | Neuroinflammation | In vitro + In vivo | Astrocytic activation via A3R as an important mediator of inflammation mediated by microglial activation | Ogawa et al., 2018 |
| A2A-R                                         | Neuron and glia plasticity | In vitro            | Astroglial glutaminergic transmission | Okada et al., 2019 |
| A2A-R                                         | Neurodegeneration | In vitro            | Overexpression upregulates astrocytic genes related to aging and astrocytic reactivity | Paiva et al., 2019 |
| A2A-R + A2B-R                                 | Neuron and glia plasticity | In vitro            | Activation of receptors in affecting synaptic networks and neuronal activity | Eusemann et al., 2015 |
| A2B-R                                         | Neurodegeneration | In vivo            | ADO as a neuroprotector | Fusco et al., 2018 |
| ADA                                           | Neurodegeneration | In vitro            | Decrease of ADA activity | Allen et al., 2019 |

ADA, adenosine deaminase; ADO, adenosine; AR, adenosine receptor; ATP, adenosine triphosphate; ENT1, equilibrative nucleoside transporter 1; LPS, lipopolysaccharide; Panx1, Pannexin 1; rENT1, rat equilibrative nucleoside transporter 1.
in neuronal disorders. ADO exerts a strong inhibitory or excitatory influence on neuronal synapses. Notably, neuronal-stem cell-derived astrocytes can develop into GB (Yao et al., 2018). Therefore, it is essential to understand the activation mechanisms of astrocytes and influence of ADO on their proliferation and function.

**ADENOSINERGIC SIGNALING IN GLIOBLASTOMA MICROENVIRONMENT**

Considering the lack of effective therapies for treating patients with GBs, new biological targets must be identified, and adenosinergic signaling has emerged as a candidate target (Azambuja et al., 2019a,b, 2020c,d,e; Yan et al., 2019). Studies by our group reported that CD73 overexpression in GB favors tumor progression (Azambuja et al., 2019b, 2020c,d,e). Moreover, A1R sensitization potentiates in vitro GB cell proliferation, migration, and invasion and contributes to TMZ resistance (Azambuja et al., 2019a). The importance of this protein in cell adhesion and invasion has been verified, as it was observed that CD73 in GB interacts with the extracellular matrix of the TME (Cappellari et al., 2012b). Using an astrocytoma cell line (U373), A2BR was described as a low-affinity receptor activated only by high concentrations of ADO, which occurs in pathological conditions such as hypoxia, and in contrast, A2AR was expressed under physiological ADO levels in the brain (Eusemann et al., 2015). Studies of CD73-FLK mice detected positive regulation of A2BR in GB, and its blockage potentiated TMZ-induced tumor cell death (Yan et al., 2019). A1R and A2AR are highly expressed in high-grade gliomas, specifically in grade III astrocytoma. In low-grade gliomas, A1R and A2AR exhibit low expression. ADO acts as a neuroprotective agent and prevents hypoxic toxicity, that is, deregulation of A1R and A2AR axis influences the metabolism of ADO in the invasive process of GB (Huang et al., 2016).

The tumor niche contains sites of hypoxia formed by the high rate of cell proliferation, without a corresponding increase in the rate of new blood vessel formation. This condition contributes to increased extracellular ATP levels, and consequently, selects the population of immunosuppressive cells present in the TME (Trabanelli et al., 2012). Interestingly, hypoxia conditions and the subsequent release of hypoxia-inducible factor-1α have been associated with the accumulation of extracellular ADO in the TME via the CD39-CD73 axis and further signaling through A2AR (Hatfield et al., 2014). Torres et al. (2019) reported that extracellular ADO production was higher in hypoxia conditions to promote cell migration and invasion in a hypoxia-inducible factor-2 dependent process, whereas A3R blockade reversed this effect. This corroborated the findings of Niechi et al. (2019), who showed that ADO depletion decreases tumor aggressiveness. In addition, clinical trials of cancer immunotherapy targeting the “hypoxia-adenosinergic pathway” through hyperoxic breathing stimulation and A2AR blockage in combination with conventional anti-PD1/PDL1 immunotherapy are underway (Ohta et al., 2006; Hatfield et al., 2015; Hatfield and Sitkovsky, 2020). These trials are reporting promising results in patients refractory to current therapies (Fong et al., 2020; Willingham et al., 2020). However, it is important to highlight the lack of studies on the therapeutic effect in human CNS tumors.

The release of EVs from tumor cells supports the ability of GBs to communicate with distant cells. Interestingly, the content of EVs reflects the activation state of the mother cell; hence, tumor cells can proliferate and modulate acceptor cells (Matarredona and Pastor, 2019; Zhang et al., 2019; Schuurmans et al., 2020). Studies of EVs are emerging and have shown promising results regarding their ability to maintain a propitious niche for tumor development, as they can modulate immune, epithelial, and glial cell signaling (Benito-Martin et al., 2015; Whiteside, 2017; Almeida et al., 2019; Boomgarden et al., 2020). Particularly, glioma cell lines as well as primary cultured cells released EVs capable of promoting M2-like activation of tumor-associated macrophages (Azambuja et al., 2020b). Moreover, exosomes, a subclassification of EVs, carry ADO and its products, such as inosine, hypoxanthine, and xanthine, which further contribute to independent adenosinergic signaling (Azambuja et al., 2020a; Ludwig et al., 2020).

Among the non-neoplastic cells comprising the TME, astrocytes stand out because of their high phenotypic similarity to GB cells (Galland et al., 2019). As mentioned earlier in this review, the astrocyte spectrum of activation of the A2-like phenotype is associated with the success of GB progression. Astrocyte phenotypic modulation can be attributed to GB, further supporting the invasion and resistance to therapy (Oushy et al., 2018; Hallal et al., 2019). One of the main functions of ADO in the extracellular environment is to act as a potent immunosuppressive mediator, which benefits tumor progression (Linden, 2011; Tozaki-Saitoh et al., 2011; Allard et al., 2016; Arab and Hadjati, 2019).

Therefore, in agreement with the results of studies using other non-transformed cells comprising the TME, such as macrophages and microglia, the purinergic receptors and ectonucleotidases may be integral components affecting the phenotypic differentiation of tumor-associated astrocytes (Figure 2C). A better understanding of the crosstalk among microglia, astrocytes, and tumor cells may reveal innovative therapeutic options based mainly on adenosinergic signaling to overcome GB progression.

**ADENOSINERGIC SIGNALING AS A THERAPEUTICAL STRATEGY FOR GLIOBLASTOMA**

Considering the present review, it is possible to understand the importance of astrocytes in maintaining homeostasis in the brain and the effective participation of ATP and ADO signaling in several processes related to health and disease. As the main source of ADO in the CNS is extracellular ATP metabolism, regulation of the hydrolysis of AMP to ADO may play a crucial role in maintaining GB-associated immunosuppression and may be an additional alternative for GB treatment in combination with standard radio- and chemotherapy with TMZ. Indeed, studies have shown the potential of P1 receptor antagonism for anti-glioma therapy. For example, the A2AR blockage would
Debom et al. Adenosinergic Signaling and Tumor-Associated Astrocytes

FIGURE 3 | Adenosinergic signaling as a therapeutic target for GB treatment. (1) After hypoxia or other insults, microglia and astrocytes become reactive, contributing to the release of ATP into the extracellular space. (2) Our hypothesis is that rapid conversion of ATP to ADO via CD73 activity expressed by both tumor cells and A2-astrocytes in the TME promote immune escape. (3) ADO can sensitize P1 receptors, mainly A2AR, contributing to the maintenance of escape from immune surveillance, and consequently, increasing tumor malignancy and progression. (4) ADO promotes an immunosuppressive TME, which inhibits T lymphocyte recruitment and induces M2-like macrophage/microglia polarization. (5) In contrast, a therapeutic approach blocking CD73 may alter this entire pathway, leading to decreased extracellular ADO. (6) A decreased ADO concentration in the TME may contribute to A1-astrocyte polarization and consequent impairment of tumor growth. A1-astrocytes overexpress A1R, A2BR, and A3R, but this effect has not been elucidated in tumors. (8) In summary, a therapeutic approach aimed at blocking adenosinergic signaling would establish an immune-attractive tumor microenvironment, resulting in the recruitment of effective immune cells to combat tumor cells. ATP, adenosine triphosphate; AMP, adenosine monophosphate; ADO, adenosine; siRNA, small interfering RNA; TME, tumor microenvironment.

Concluding Remarks

The present review raises the hypothesis that reactive astrocytes are involved in the progression of brain tumors, such as GB. As astrocytes are instrumental to the microenvironment of the CNS, contribute to recovering GB chemosensitivity to TMZ (Yan et al., 2019). In addition, the pharmacological blockade of CD73 using a selective inhibitor, the α,β-methylene adenosine 5′-diphosphate (APCP) have been described as a potential therapy for several tumors, such as melanoma, breast cancer, and gliomas (Koszalka et al., 2014; Tomczyk et al., 2018).

By using CD73 as a molecular target and nanotechnology as a strategy for siRNA delivery to the CNS, our group demonstrated the potential of CD73 inhibition and knockdown for controlling in vitro and in vivo tumor progression (Azambuja et al., 2019a). According to our studies, the pharmacological inhibition as well as the silencing of CD73 impaired the protumor activities of CD73, decreasing the tumor volume and providing an opportunity to overcome chemoresistance and/or improve the TMZ effect (Azambuja et al., 2019a, 2020c,d). We also recently reported the impact of blocking CD73 and consequent decrease in ADO availability on the levels of M2-like macrophages in the TME in a preclinical rat GB model (Azambuja et al., 2020e; Figure 3). These data strongly indicate the potential of using therapeutics to modulate the TME via purinergic constituents to re-establish the antitumor activity of immune cells. Nonetheless, the CD73 inhibition may not be always therapeutically helpful for tumors as seen for the GB and the specific biological characteristics of each tumor should be considered. For example, in medulloblastoma, the CD73 expression is a marker associated with better prognosis of patients (Cappellari et al., 2012a, 2015).

Considering the similar features and responses of microglia and astrocytes in the TME, the ADO pathways may also be altered in astrocytic polarization, providing a therapeutic approach for treating patients with GB. Moreover, the participation of ADO and P1 receptors in the blood-brain barrier-associated properties is another interesting point for discussion about the therapeutical potential of ADO signaling blockage. As extensively described by Bynoe et al. (2015), both astrocyte’s end-feet and endothelial cells of the blood-brain barrier express those receptors, especially A1R and A2AR. Therefore, P1R mediated-signaling is decisive to regulate the permeability of macromolecules, inflammatory cells, and even therapeutic drugs/cells into the CNS (Bynoe et al., 2015).
they can be corrupted by tumor cells and directly and indirectly participate in the TME, thus regulating crosstalk among tumor, glial, and endothelial cells.

Notably, CD73 knockdown or inhibition decreases in vitro and in vivo GB growth, and CD73 is an interesting target for brain tumor therapy. Additionally, adenosinergic therapy can be applied in most TME cells to inactivate not only transformed cells but also tumor-associated cells, including A2-astrocytes that support tumor progression.

OPEN QUESTIONS

Considering the recent advances described in this review, although astrocyte participation in healthy and diseased brain biology has been well-established, there is no general agreement on astrocytic polarization in different phenotypes according to the nature of the injury, nor specifically in brain tumors. Recently, astrocytes were proposed to be involved in neuroinflammation. Further studies are needed to better describe their full characteristics and key features in different disorders involving immune components. Moreover, studies of astrocytic polarization are necessary to understand if different injury conditions lead to the production of different subpopulations of A1/neurotoxic and A2/neuroprotective astrocytes, or to transition stages until the fully reactivated cell state is reached.

Few studies have focused on the link between purinergic signaling and astrocyte participation in the tumor niche constitution. Considering the key role of the gliotransmitter ATP and its metabolite ADO on astrocyte functions, the specific factors involved in purinergic signaling, particularly adenosinergic signaling, as potential makers of astrocyte polarization should be further examined. Additionally, the contribution of ADO as a potent modulator of immune responses may directly influence astrocytic polarization, which requires further analysis. Moreover, the contribution of astrocyte-microglia crosstalk may be another key element in the outcome of GB, as well as for other CNS pathologies.

Finally, considering the genetic and phenotypic similarities of astrocytes and GB cells, tracing possible molecular markers or determining the signature of different astrocytic phenotypes is a crucial strategy for determining the contribution of non-malignant astrocytes in brain tumor physiology and establishing more effective therapeutic approaches.

AUTHOR CONTRIBUTIONS

GD and DR selected articles in PubMed and analyzed articles. GD created Table 1. DR assembled the figures. EB acquired the funding, supervised, and guided the entire work. All authors conceived the idea of studying the role of purinergic signaling in astrocytes and tumor progression, wrote and edited the article, and reviewed and edited the final text.

FUNDING

The authors would like to thank the Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul (FAPERGS; process number 19/2551-0001779-0; PRONEX – 16/2551-000473-0), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES; code 001), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ process number 312187/2018-1; 400882/2019-1). GD, DR, and EB are recipients of CAPES or CNPq fellowships.

ACKNOWLEDGMENTS

We thank C. B. Haas, J. A. M. Barbuto, and A. A. Rasia Filho for providing expert advice and suggestions on the manuscript.

REFERENCES

Adzic, M., and Nedeljkovic, N. (2018). Unveiling the role of Ecto-5’-nucleotidase/CD73 in astrocyte migration by using pharmacological tools. Front. Pharmacol. 9:153. doi: 10.3389/fphar.2018.00153
Adzic, M., Stevanovic, I., Josipovic, N., Laketa, D., Lavrnja, I., Bjelobaba, I. M., et al. (2017). Extracellular ATP induces graded reactive response of astrocytes and strengthens their antioxidative defense in vitro. J. Neurosci. Res. 95, 1053–1066. doi: 10.1002/jnr.23950
Agostinho, P., Madeira, D., Dias, L., Simões, A. P., Cunha, R. A., and Canas, P. M. (2020). Purinergic signaling orchestrating neuron-glia communication. Pharmacol. Res. 162:105253. doi: 10.1016/j.phrs.2020.105253
Allard, B., Allard, D., Buisseret, L., and Stagg, J. (2020). The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611–629. doi: 10.1038/s41571-020-0382-2
Allard, B., Beavis, P. A., Darcy, P. K., and Stagg, J. (2016). Immunosuppressive activities of adenosine in cancer. Curr. Opin. Pharmacol. 29, 7–16. doi: 10.1016/j.coph.2016.04.001
Allard, B., Longhi, M. S., Robson, S. C., and Stagg, J. (2017). The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. ImmunoL Rev. 276, 121–144. doi: 10.1111/imr.12528
Allen, S. P., Hall, B., Castelli, L. M., Francis, L., Woof, R., Siskos, A. P., et al. (2019). Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain 142, 586–605. doi: 10.1093/brain/awy353
Almeida, V. H., Rondon, A. M. R., Gomes, T., and Monteiro, R. Q. (2019). Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis. Cells 8:716. doi: 10.3390/cells8070716
Arab, S., and Hadjati, J. (2019). Adenosine blockade in tumor microenvironment and improvement of cancer immunotherapy. Immune Netw. 19, 1–19. doi: 10.4110/in.2019.19.e23
Azambuja, J. H., Gelsleichter, N. E., Beckenkamp, L. R., Iser, I. C., Fernandes, M. C., Figueiró, F., et al. (2019a). CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth. Mol. Neurobiol. 56, 3260–3279. doi: 10.1007/s12035-018-1240-4
Azambuja, J. H., Ludwig, N., Braganhol, E., and Whiteside, T. L. (2019b). Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. Front. Immunol. 10.3389/fimmu.2019.02164
Azambuja, J. H., Ludwig, N., Yerneni, S. S., Braganhol, E., and Whiteside, T. L. (2020a). Arginase-1+ exosomes from reprogrammed macrophages promote glioblastoma progression. Int. J. Mol. Sci. 21:3990. doi: 10.3390/ijms21113990
Azambuja, J. H., Ludwig, N., Yerneni, S., Rao, A., Braganhol, E., and Whiteside, T. L. (2020b). Molecular profiles and immunomodulatory activities of glioblastoma-derived exosomes. Neurooncol. Adv. 2, 1–11. doi: 10.1093/noaax056
proliferation independently of adenosine receptor activation. J. Neurochem. 153, 455–467. doi: 10.1111/jn.14937

Martin-Fernández, M., Jamison, S., Robin, L. M., Zhao, Z., Martin, E. D., Aguilar, J., et al. (2017). Synapse-specific astrocyte gating of amygdala-related behavior. Nat. Neurosci. 20, 1540–1548. doi: 10.1038/nn.4649

Matarredona, E. R., and Pastor, A. M. (2019). Extracellular Vesicle-Mediated Communication between the Glioblastoma and Its Microenvironment. Cells 9:96. doi: 10.3390/cells9010096

Matias, D., Predes, D., Niemeyer Filho, P., Lopes, M. C., Abreu, J. G., Lima, F. R. S., et al. (2017). Microglia-glioblastoma interactions: new role for Wnt signaling. Biochim. Biophys. Acta 1868, 333–340. doi: 10.1016/j.bbadis.2017.05.007

Matos, M., Augusto, E., Agostinho, P., Cunha, R. A., and Chen, J.-F. (2013). Antagonistic Interaction between Adenosine A2A Receptors and N(k+)ATPase- 2 Controlling Glutamate Uptake in Astrocytes. J. Neurosci. 33, 18492–18502. doi: 10.1523/JNEUROSCI.1828-13.2013

Matos, M., Shen, H., Augusto, E., Wang, Y., Wei, C. J., Wang, Y. T., et al. (2015). Deletion of Adenosine A2A Receptors From Astrocytes Disrupts Glutamate Homeostasis Leading to Psychomotor and Cognitive Impairment: relevance to Schizophrenia. Biol Psychiatry 78, 763–774. doi: 10.1016/j.biopsych.2015.02.026

Mederos, S., Hernández-Vivanco, A., Ramirez-Franco, J., Martín-Fernández, M., Navarrete, M., Yang, A., et al. (2019). Melanopsin for precise optogenetic activation of astrocyte-neuron networks. Glia 67, 915–934. doi: 10.1002/glia.23750

Mega, A., Hartmark, M., Leiss, L. W., Tobin, N. P., Miletic, H., Sleire, L., et al. (2020). Astrocytes enhance glioblastoma growth. Glia 68, 316–327. doi: 10.1002/glia.23718

Minkiewicz, J., de Rivera Vaccari, J. P., and Keane, R. W. (2013). Human astrocytes express a novel NLRP2 inflammasome. Glia 61, 1113–1121. doi: 10.1002/glia.22499

Moidunny, S., Vinet, J., Wesseling, E., Bijzet, J., Shieh, C. H., van Ijzendoorn, M. C., et al. (2015). Astrocytes shed extracellular vesicles that contain fibroblast growth factor-2 and vascular endothelial growth factor. Int. J. Mol. Med. 36, 63–69. doi: 10.3892/ijmm.2015.2163

Qi, Q., D’F., and Jones, J. A. (2017). The Microenvironmental Landscape of Brain Tumors. Cancer Cell 31, 326–341. doi: 10.1016/j.ccell.2017.02.009

Rajendran, L., Bali, J. M., Barr, M. E., Kramer-Albers, E. M., Picou, F., et al. (2014). Emerging Roles of Extracellular Vesicles in the Nervous System. J. Neurosci. 34, 15482–15489. doi: 10.1523/JNEUROSCI.3258-14.2014

Rebola, N., Lujan, R., Cunha, R. A., and Mulle, C. (2008). Adenosine A2A Receptors Are Essential for Long-Term Potentiation of NMDA-EPSCs at Hippocampal Mossy Fiber Synapses. Neuron 57, 121–134. doi: 10.1016/j.neuron.2007.11.023

Redic, Z. B., Malatiati, S. A., Al-Bader, M., and Al-Sarraf, H. (2010). Effects of hypoxia, glucose deprivation and recovery on the expression of nucleoside transporters and astroglial adenosine uptake in primary culture of rat cortical astrocytes. Neurochem. Res. 35, 1434–1444. doi: 10.1007/s11064-010-0203-6

Rodrigues, R. J., Tomé, A. R., and Cunha, R. A. (2015). ATP as a multi-target danger signal in the brain. Front. Neurosci. 9:148. doi: 10.3389/fnins.2015.00148

Roesch, S., Rapp, C., Dettling, S., and Herold-Mende, C. (2018). When immune cells turn bad—tumor-associated microglia/macrophages in glioma. Int. J. Mol. Sci. 19:436. doi: 10.3390/ijms19020436

Scenes, E., Velilek, L., and Velilévková, J. (2019). Astrocyte and Neuronal Pannexin1 Contribute Distinctly to Seizures. ASN Neuro 11:1759091419833502. doi: 10.1177/1759091419833502

Schalla, M. A., and Stengel, A. (2019). Pharmacological Modulation of Ghrelin to Induce Weight Loss: successes and challenges. Curr. Diab. Rep. 19:102. doi: 10.1007/s11892-019-1211-9

Scharbarg, E., Daenens, M., Lemaitre, F., Geoffroy, H., Guille-Collignon, M., Gallopin, T., et al. (2016). Astrocyte-derived adenosine is central to the hypnogenic effect of ghrelin. Sci. Rep. 6, 1–14. doi: 10.1038/srep19107

Schmitt, L. I., Sims, R. E., Dale, N., and Hayden, P. G. (2012). Wakefulness affects synaptic and network activity by increasing extracellular astrocyte-derived adenosine. J. Neurosci. 32, 4417–4425. doi: 10.1523/JNEUROSCI.3689-11.2012

Schuurmans, C., Balakrishnan, A., Roy, S., Fleming, T., and Leong, H. S. (2020). The emerging role of extracellular vesicles in the glioma microenvironment: biogenesis and clinical relevance. Cancers 12, 1–25. doi: 10.3390/cancers12071964

Singh, A. V., Raymond, M., Pace, F., Certo, A., Zuidema, J. M., McKay, C. A., et al. (2015). Astrocytes increase ATP exocytosis mediated calcium signaling in response to microgroove structures. Sci. Rep. 5, 1–8. doi: 10.1038/srep07847

Singh, M., Garrison, J. E., Wang, K., and Sheffield, V. C. (2019). Absence of BBSome function leads to astrocyte reactivity in the brain. Mol. Brain 12, 1–19. doi: 10.1186/s13041-019-0466-z

Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638–647. doi: 10.1016/j.tins.2009.08.002

Sofroniew, M. V., and Vinters, H. V. (2010). Astrocytes: biology and pathology. Acta Neuropathol. 119, 7–35. doi: 10.1007/s00401-009-0619-8
Stout, C. E., Costantini, J. L., Naus, C. C. G., and Charles, A. C. (2002). Intercellular Calcium Signaling in Astrocytes via ATP Release through Connexin Hemichannels. J. Biol. Chem. 277, 10482–10488. doi: 10.1074/jbc.M109902200

Streptos, D., Markouli, M., Klonou, A., Piperi, C., and Papavassiliou, A. G. (2020). Insights in the immunobiology of glioblastoma. J. Mol. Med. 98, 1–10. doi: 10.1007/s00109-019-01835-4

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., et al. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New Engl. J. Med. 352, 987–996. doi: 10.1056/NEJMoa043330

Suadicani, S. O., Iglesias, R., Wang, J., Dahl, G., Spray, D. C., and Scemes, E. (2012). ATP signaling is deficient in cultured pannexin1-null mouse astrocytes. Glia 60, 1106–1116. doi: 10.1002/glia.22338

Synowitz, M., Glass, R., Färber, K., Markovic, D., Kronenberg, G., Herrmann, K., et al. (2006). A 1 Adenosine Receptors in Microglia Control Glioblastoma-Host Interaction. Cancer Res. 66, 8550–8557. doi: 10.1158/0008-5472.CAN-06-0365

Tirosh, I., and Suvà, M. L. (2018). Dissecting human gliomas by single-cell RNA sequencing. Neuronurobiology 20, 37–43. doi: 10.1093/neuron/oxw126

Tomczyk, M., Mierzejewska, P., Smolinska, E., and Smolenski, R. T. (2018). The metabolism of ecto-5′-nucleotidase (CD73) inhibitor-a,b-methylene adenosine diposphate in BALB/c mice. Nucleosides Nucleotides Nucleic Acids 37, 709–716. doi: 10.1080/15257770.2018.1498952

Torres, A., Erices, J. I., Sanchez, F., Ehrenfeld, P., Turchi, L., Virolle, T., et al. (2019). Extracellular adenosine promotes cell migration/invasion of Glioblastoma Stem-like Cells through A3 Adenosine Receptor activation under hypoxia. Cancer Lett. 446, 112–122. doi: 10.1016/j.canlet.2019.01.004

Tozaki-Saitoh, H., Tsuda, M., and Inoue, K. (2011). Role of Purinergic Receptors in CNS Function and Neuroprotection. Advance Pharmacol. 61, 495–528. doi: 10.1016/S0065-2156(10)40001-8

Trabanelli, S., Očadlíková, D., Guinellin, S., Curti, A., Salvestrini, V., de Paula Vieira, R., et al. (2012). Extracellular ATP Exerts Opposite Effects on Activated and Regulatory CD4+ T Cells via Purinergic P2 Receptor Activation. J. Immunol. 189, 1303–1310. doi: 10.4049/jimmunol.1103800

Verano-Braga, T., Gorshkov, V., Munthe, S., Sørensen, M. D., Kristensen, B. W., et al. (2018). Intercellular Calcium Signaling in Astrocytes via ATP Release through Pannexin1. J. Neurin. 98, 239–389. doi: 10.1152/physrev.00042.2016

Wei, R., Liu, S., Zhang, S., Min, L., and Zhu, S. (2020). Cellular and Extracellular Components in Tumor Micromilieu and Their Application in Early Diagnosis of Cancers. Analyt. Cell. Pathol. 2020, 1–13. doi: 10.1155/2020/6283796

Wesseling, P., and Capper, D. (2018). WHO 2016 Classification of gliomas. Neuropathol. Appl. Neurobiol. 44, 139–150. doi: 10.1111/nan.12432

Whiteside, T. L. (2017). The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy. Future Oncol. 13, 2583–2592. doi: 10.2217/fon-2017-0343

Wilhelmsen, U., Bushong, E. A., Price, D. L., Smarr, B. L., Pfung, V., Terada, M., et al. (2006). Redefining the concept of reactive astrocytes as cells that remain within their unique domains upon reaction to injury. Proc. Natl. Acad. Sci. 103, 17153–17158. doi: 10.1073/pnas.0602841103

Willingham, S. B., Hotson, A. N., and Miller, R. A. (2020). Targeting the A2AR in cancer; early lessons from the clinic. Curr. Opin. Pharmacol. 53, 126–133. doi: 10.1016/j.coph.2020.08.003

Wink, M. R., Braganhol, E., Tamajusuku, A. S. K., Casali, E. A., Karl, J., Barreto-Chaves, M. L., et al. (2003). Extracellular adenosine nucleotides metabolism in astrocyte cultures from different brain regions. Neurochem. Int. 43, 621–628. doi: 10.1016/S0197-0186(03)00994-9

Wink, M. R., Braganhol, E., Tamajusuku, A. S. K., Lenz, G., Zerbini, L. F., Libermann, T. A., et al. (2006). Nucleoside triphosphate diphosphohydrolase-2 (NTPDasc2/CD39L1) is the dominant ectonucleotidase expressed by rat astrocytes. Neuroscience 138, 421–432. doi: 10.1016/j.neuroscience.2005.11.039

Yan, A., Joachims, M. L., Thompson, L. F., Miller, A. D., Canoll, P. D., and Bryne, M. S. (2019). CD73 promotes glioblastoma pathogenesis and enhances its chemoresistance via A2B adenosine receptor signaling. J. Neurosci. 39, 4387–4402. doi: 10.1523/JNEUROSCI.1118-18.2019

Yao, M., Li, S., Wu, X., Diao, S., Zhang, G., He, H., et al. (2018). Cellular origin of glioblastoma and its implication in precision therapy. Cell. Mol. Immunol. 15, 737–739. doi: 10.1038/cmi.2017.159

Zamanian, J. L., Xu, L., Foo, L. C., Nouri, N., Zhou, L., Giffard, R. G., et al. (2012). Genomic Analysis of Reactive Astrogliosis. J. Neurosci. 32, 6391–6410. doi: 10.1523/JNEUROSCI.6221-11.2012

Zarrinnamayeh, H., and Territo, P. R. (2020). Purinergic Receptors of the Central Nervous System: biology, PET Ligands, and Their Applications. Mol. Imaging 19, 1–26. doi: 10.1177/1350626219827609

Zhang, Y., Liu, Y., Liu, H., and Tang, W. H. (2019). Exosomes: biogenesis, biologic function and clinical potential. Cell. Biosci. 9, 1–18. doi: 10.1186/s13578-019-0282-2

Zorec, R., Verkratisky, A., Rodríguez, J. J., and Papura, V. (2016). Astrocytic vesicles and gliotransmitters: slowness of vesicular release and synaptobrevin2-laden vesicle nanoarchitecture. Neuroscience 323, 67–75. doi: 10.1016/j.neuroscience.2015.02.033

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Debom, Rubenich and Braganhol. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.